HUE032306T2 - N-[4-(kinolin-4-iloxi)ciklohexil(metil)](hetero)arilkarboxamidok mint androgén receptor antagonisták, elõállításuk és gyógyászati termékekként történõ alkalmazásuk - Google Patents
N-[4-(kinolin-4-iloxi)ciklohexil(metil)](hetero)arilkarboxamidok mint androgén receptor antagonisták, elõállításuk és gyógyászati termékekként történõ alkalmazásuk Download PDFInfo
- Publication number
- HUE032306T2 HUE032306T2 HUE13731325A HUE13731325A HUE032306T2 HU E032306 T2 HUE032306 T2 HU E032306T2 HU E13731325 A HUE13731325 A HU E13731325A HU E13731325 A HUE13731325 A HU E13731325A HU E032306 T2 HUE032306 T2 HU E032306T2
- Authority
- HU
- Hungary
- Prior art keywords
- cyclohexyl
- trans
- oxy
- methyl
- stands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Claims (5)
- Sxsíbaösiini iaöny:pö!«ok I. ti) általános kcpietuil, amelyben 8: jelemen H. <. iano. Hirnr. klór vagy bron?. Λ jftentésb Rail vagy 5-tags.t hetesosnl, ahol a fenil vagy az $ -tagú hcteioani adott esetben szubsztitnált a kovdkeeök közit! egymástól iVsggeiierH'ii választón egy. kenő vagy hárótb s/ubsdin;vnssel: fejöven. ciano alkik·:, haloaikil·, eikbaíkii-. feneroeikhk hnlroxi. alkovo, ityotyikoxk eikfedkilom·. amino·; aikijamino·. diaikthmino·, cikloalkiUmsino·. alkiRRbfekfernino··. dieikkutíkilammn-. nlkiikakossiiamino-. çikiôâlîkÜkài^oiîiláfíáîïïdailílisanltaáil-,: cíkt:8álk:i|saí'tánll\^ iü;íkitiiiKuïiÎïήsfegçiiikIoáίΙίί|$ίκύ1ΐΐ>ηífe. amibosfeífefek aikfetninos/.niíbnik cikkadl< i]amiΓ^·>svιnî\o·!ls arKcmikarboni!^g;opv»rt: 'S!·" 0. I: vagy 2:, vagy á köveíkegök; agyi ke: sói, szolvátjai vagy ; y<ï:nak vzoivatjni. J, Az i;> igénypont szerint; vegyiden azzal jellemezve. hogy R* jelenítse H, cianm Utor y agy bróng A jelentése fers il vagy 5-íayá haicioanl, ahol a leni! vagy az v-tagó hoteis>an; adod esesben szabsz* imáit a következők közi; ^mástól: '-vltoÄtl '§gy vagy· MM .kxulteJÍ«««ss«l: halogén,., «isao·, alkik haioulkílcs< sport: n ·« 0 vagy vagy a: következik egyike; sok yzolvaiai vagy sóinak szó Kát jak 3. A? Is igénypont \/.ehnf.i vegyibe· a/.zal jellemezve. hogy fi1 jelentése H. bto-m, dano vagy ílnor; Λ jelentése terül vagy S-tagú heteroarii. ahol ;i leni! vagy a? 5-tag.ö heteroari! adoti esetben szubsztunait á köve* \vzus kbzal z >\masfei bigéét e mi ' t’;s ' <. \ < η· ' ,ηο s/oosztitm pest í laot *la mm neta vagy miluonnetii; n" 0 vagy 1, 119941 LG/Ho vagy a következők egyike: sok szöívMai vagy sdmakvzo! váljak •4.·^«. I, igdóypom szentpi vegyület, azzal jeíietnezvig hogy A jeieiitatv^öií, steí a íertlí adón esotbea rV'ubs.vauáU a következők könií egymástól küy.gci lenül választott egy vagy keik; szulvvíiük-imeí: fer, klór, ciano, raeuk tnfUiormetil.
- 5, Az I. igénypont szerinti vegyidet. azzal je-iiemezvsx hogy A jeleoiése fenil, aho! a tend adott esetbe« Ühorsiodxxzntueossei sx.obxzti'.uáU. ft. Αχ í. igénypont szerion vegyidet, a következők közöl választva: Ν··( ; t:;«;s/-4-[i 8 -tkíorkaKdin- 4-4l}oxi ieikiohexd ; meuO'^-dinod-ieu/andd, 'N-(tra«sx-4-[{8-i:a(;!«knioii!o4«l)oxdcik!obe>.d ; -53-karbovaut·:>.ί. N-jlrtmsz^-ia-kiooliJoNiKïkîohextlj-.k-l-ciiriiîarbetizamid, hi-<{tfat}sX'<4-ft8--f1uorfc-Í«oiin*4'-d)oxj}c-íyöb«KÍI|me«i)-3?-njet>bzoxaxo'l~4'--karfeioxamtá·.· Ν J't8d5iH>rkkóolinv4--dkíKi|c:ikíohexd:rOit^rii)-izoxasd-5'íoirb<o;atríi<!i N -( | tranxz-4 -((8- fiunrkKKdln-^-djoxndkiobexi I J met ildxoxazoí--v-karboxatn id, N-(ítxans/-4-j(84luorki«o!m--4-d}ox!|clklo!Ko:iíjo'tí«ií)--5-nK4dixoxa/okH-karboxafídsi N -( J tranxz~4 -| (8 - UtKiti: moiht-4 - <1)·:>χι jc. ikloho: il j mef i! )·· i B-pinmd- 4-k arboxarn ai, N-î(îranax-4-(4--ki-K>hkxxik;ikkdao;ilinK-tifi k4-diûuorb<:f>7.anikk N i trana? -4 -{4-k inni I loxi tc. iklohexil j-uet ? S î -3- OoorbeHzatrtki, N -1 i transx--4 -(4:-k ino; I ίο xl )c Ik lohe S j.- 5 one! i I ixoxazoi-e -karhsixamid. N-itran5x-i-{{S--bfömkmobn“44i>oxtittklohexiii-j-ti«<>rbm2amiä» N.'iSS3.^á*“4:*|i(;S-brö:i3^k:«í!e3l;i:n-4^tÍ)öX;íÍbÍk:Íiö;Íli.e>í'íí|''.3:.4'^dlúiuí5rtee«:xsm:N:>. M~ i transzod- íp-bt ótok ΐίτοί h t-44 I }ox ijt i ki 0 hex it14~ei anoheozaibi d. M - Jtraniiit-'-d-fgyki-brófstl: inotb«-4 AI îosd)clk!oho>;u ; - ?>- ritjco - 4 (trsnuor:ni-M;n>bie!:^aniki. N - ! transz -4- U 8- hrómfc inoI i«-4- bjoxgdklohexii] -A-dlooHíOOZaid id, Id- jtranszÁ- ^S-broiokino ϋο··4»d jdx I ]e ik lobe xilj d-kíóMAáttorbenzsmid, M- Utaoaz-4-(-i--kino!ilox;K'iklohei'.:ilf'-3-tlaorban/a(oid, N4}ti-a>\&?-4-[(ii-UrftmkiooUo-4-sf)oxt}cikiohexi!î»n«ttl)-5-nietîi!i'.oxazoi-3-karbi!ôsaïïïtd, N-{{tranx2-4-((S*brotnktncdh4--d)ox!jcikioHé#^ttfe*!áz«i!>-S-lNá;t^Oíí:amy, N4iitao;ot-4-(4-!.;inoiiiov;Kikk4e>diiniot!i{-4-öiätuy^n:«5!Aid^ N - tra tn x - i - [( 8 - d a n ok i noí io -4 - s I );>x ? Je I k io be x ί ï1 -ô - il oorbebzata id, N:-tíansx-4-i(8-ciar!okitH)íio4-d)oxi|cikiohcxí!j:A4-d!ÍltKHÍK-n>-.aiT!Íd, N-t; anxz-4 -j (8-claHokstK)ii)v4--iî}ox!|cik iobexil í -4 - fioorbeozannd, N-ítraosZ'dd^g-ei&nokiaoloy-d-ilkJkipkíobvxtíi-S'ntetittztföaztókS-karböxsaíiC i-klor-N-'(transz-4 ;(8-eaano!··•nohn-A-d'tox!jcfklohextiS-4-;1 aotbettzvnnd, N'-íiraoa>: -4-Í(g-ci;aK:-kirH)Í!ti'4-ti)ox!|vik!obex:l.! -d-rUKir-d -irictUbco/iamid. 4--kldr'N-|tranxz4-;(8--c;ianokit3<ditt4-4:l)osi|eikiohgxil:} •3dTuorbe?t«ami<k Id^traösz-#||8~eiattok tooim-4·« !jtixildkldhexill "O^-ddluorbenzaabd, N-{, ? äran&?-4~f<8'Ctaii<ikinoljr:—i-si.ïi>v s jcikKihuiN *ä ; metü ïîîx:x;ïi = t!- 3-kus boxasrs id. M0iirânsx^4-|(8*:e|;ffî^iftolin--^ihoxMjcikiohi^\ii)metilN3'nietiÎÎÂV\a/.oiv3"karbosarn;î:ii3:ÿ ?. Eljárás az l igénypord szerinti (ï\ képleiü vegyüiei vagy sók szoivàija. v agy -'Omsk szoNátfei egyikének előállítására, ss! jellemezve, hogy (fi) skálám« képiéül vegyit letetan. amelyben R' cn n jelentőse a/ I. igériyporrfösn megi'tanbwmï, reagáltanmk A-COCJ savktorxídai. amelyben A jelentése az \. jg6aype»tbM-j»eppär#^ö^' bázis jelenlétében. és: a tkapM :|ijykép!et:ü yegyijistet: .adott sMfeea· aíáíáfctpsk a megfelelő (η Aidoszérfél ésíyagy ϋά bázissal vagy savval szoívátjává, sójává és/vagy sójáftak sxoiváíjává.
- 8. Kijárás az I. igénypont szerinti (I) képlett vegyék'! vagy sík szolváijas vagy sóinak szolváüai egyikének előállítására, azzal jellemezve,, hogy (I I) általános képiéül vegyúiete;on.. araely|e«.'tJvifem|éíe«.ti^e a/. í. >gcn>-po«íbatt meghátaröMtü rsagá Itatunk A-CÛOH snvvái amelyben A jelentése az I. igénypoiiíban ntegltmärozon, megfelelő yv!p. s<.m.> íoagens „>·, havi; mieniéteeen. és a kapón. 11 ? képiéül vegyiïletet adott esetben átalakítjuk a mégfejeld (i) «ídőszerrel ès/vagy (h) bázissal vagy savval »zöiváíjává, sójává és/vagy sójának szol vauévá. 9. kijárás a;? 1, igénypédt szerinti fi) képiéül vegyüle!, amelyben R;;:ekmo, vagy sói, szolvatgíi vagy sóinak szolvátjoi egyikének előállítására. azzal je/eme, μ no··, <\ l|s aitaiamis kepletn \o >sükteíVH amelyben n és Λ jelentése a? L igpnyp®i#an:meghatározóik fè^iWê:(i*sO''feÎ!ï'âfivëf:0^iiil:f^.i;îônsk ''•cîjuk alá, és g; kapott |í;| képiéit) vegydlétek amelyben R' :: címük adott esetbost dtaiakitjuk a mégjeleRt (i) öldóaáeyröi: eVvaéy fii) bázissíd vagy savval Azoiváijáva., sóiévá és/vagy sbiüosii: szoívátjavá, iOt Äk: |,4l tgéftypoftídli «gy:ik« sxennti vegyület hipetproiitfemtív betegség;:: ík&eéiésébeii: és;vagy m:é|eMé#bííé iöneik; alkalmazásra. IS. Vagyaiéi alkalmazásba: 3: 10, igimypmtt szeri OR <i hoi a hipetprohfecadv betegség niRlrogén-tecrpsor dopenden;; hiperproüternt ív betegség-
- 12. .Az í-b. ige nypomak egyike síseririii vegyük·!tpblícSSJíiás: petefészek szindróma kezelésében és/vagv mege Imréiében tds:té;tö gíkgiíbáaásÍ'á-
- 13. Gyógyásza·! készítmény, amely tactsiteagéa a;··· í-6. tgén>perünk egyike szerinti vegyüieiet kombinációban égy tovább· .hatóanyaggal,. 14. %ógytiszait készisménv. amely tartalmazza az :14,, igénypontők egyike szerinti ve gyű letet kombinációban egy uteri., nem-toxikus. gyógyszerészedé segédanyaggát; 1 a f||) által áiiös képiéin vegyibe·ft amelyben R! és n jelentévé az i. ÍL>;n)y|x»tíbair:iyieghéíáreí%éS,
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032306T2 true HUE032306T2 (hu) | 2017-09-28 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE13731325A HUE032306T2 (hu) | 2012-06-26 | 2013-06-24 | N-[4-(kinolin-4-iloxi)ciklohexil(metil)](hetero)arilkarboxamidok mint androgén receptor antagonisták, elõállításuk és gyógyászati termékekként történõ alkalmazásuk |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9428460B2 (hu) |
| EP (1) | EP2864291B1 (hu) |
| JP (1) | JP6181172B2 (hu) |
| KR (1) | KR20150023880A (hu) |
| AP (1) | AP3919A (hu) |
| AR (1) | AR091565A1 (hu) |
| AU (1) | AU2013283543B2 (hu) |
| BR (1) | BR112014032538A2 (hu) |
| CA (1) | CA2877786C (hu) |
| CL (1) | CL2014003443A1 (hu) |
| CO (1) | CO7170167A2 (hu) |
| CR (1) | CR20140593A (hu) |
| CU (1) | CU20140144A7 (hu) |
| CY (1) | CY1118412T1 (hu) |
| DK (1) | DK2864291T3 (hu) |
| DO (1) | DOP2014000295A (hu) |
| EA (1) | EA028063B1 (hu) |
| EC (1) | ECSP14032516A (hu) |
| ES (1) | ES2609455T3 (hu) |
| HR (1) | HRP20161745T1 (hu) |
| HU (1) | HUE032306T2 (hu) |
| IL (1) | IL236146B (hu) |
| JO (1) | JO3342B1 (hu) |
| LT (1) | LT2864291T (hu) |
| MA (1) | MA37700B1 (hu) |
| ME (1) | ME02590B (hu) |
| MX (1) | MX2014016054A (hu) |
| NZ (1) | NZ703100A (hu) |
| PE (1) | PE20150154A1 (hu) |
| PH (1) | PH12014502869B1 (hu) |
| PL (1) | PL2864291T3 (hu) |
| PT (1) | PT2864291T (hu) |
| RS (1) | RS55500B1 (hu) |
| SG (1) | SG11201408254UA (hu) |
| SI (1) | SI2864291T1 (hu) |
| TN (1) | TN2014000532A1 (hu) |
| TW (1) | TWI600646B (hu) |
| UA (1) | UA115447C2 (hu) |
| UY (1) | UY34881A (hu) |
| WO (1) | WO2014001247A1 (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106413715A (zh) * | 2014-04-22 | 2017-02-15 | 林伯士艾瑞斯公司 | Irak抑制剂和其用途 |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3452029A4 (en) * | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| WO2017192813A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6686376B2 (en) | 2000-06-23 | 2004-02-03 | Eli Lilly And Company | Methods and compounds for inhibiting MRP1 |
| CA2454538A1 (en) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same |
| AU2003261974A1 (en) | 2002-09-11 | 2004-04-30 | Kureha Chemical Industry Company, Limited | Amine compounds and use thereof |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| DE602004022633D1 (de) | 2003-01-30 | 2009-10-01 | Boehringer Ingelheim Pharma | 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| EP1725238A4 (en) | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 MUSCARINACETYLCHOLINE RECEPTOR ANTAGONISTS |
| SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (en) | 2004-05-27 | 2005-12-15 | Jack Saffron | Feeding dish to prevent pest infestation |
| BRPI0517567A (pt) | 2004-11-09 | 2008-06-17 | Smithkline Beecham Corp | composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| WO2007091694A1 (en) | 2006-02-06 | 2007-08-16 | Showa Denko K.K. | Whitening dermatological preparations |
| US20110053931A1 (en) | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (en) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Polycyclic molecular compounds |
| JP5634263B2 (ja) | 2007-08-16 | 2014-12-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナゾリンジオンキマーゼ阻害剤 |
| EP2220050A2 (en) * | 2007-10-26 | 2010-08-25 | The Regents Of The University Of California | Diarylhydantoin compounds as androgen receptor modulators |
| AU2009246263B2 (en) | 2008-05-14 | 2014-08-21 | Amgen Inc. | Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer |
| US20110229469A1 (en) | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| TW201116525A (en) | 2009-07-21 | 2011-05-16 | Gilead Sciences Inc | Inhibitors of flaviviridae viruses |
| JP2013504531A (ja) | 2009-09-11 | 2013-02-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 抗癌薬としての置換(ヘテロアリールメチル)チオヒダントイン |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
-
2013
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Ceased
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 CA CA2877786A patent/CA2877786C/en not_active Expired - Fee Related
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/en not_active Ceased
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/hu unknown
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/en active Active
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/me unknown
- 2013-06-24 US US14/408,876 patent/US9428460B2/en not_active Expired - Fee Related
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869B1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
-
2016
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2958928B1 (de) | Estra-1,3,5(10),16-tetraen-3-carboxamide zur inhibierung von 17.beta.-hydroxysteroid dehdrogenase (akr1c3) | |
| UA124474C2 (uk) | БЕНЗІЗОТІАЗОЛЬНІ, ІЗОТІАЗОЛО[3,4-b]ПІРИДИНОВІ, ХІНАЗОЛІНОВІ, ФТАЛАЗИНОВІ, ПІРИДО[2,3-d]ПІРИДАЗИНОВІ Й ПІРИДО[2,3-d]ПІРИМІДИНОВІ ПОХІДНІ ЯК ІНГІБІТОРИ G12C KRAS ДЛЯ ЛІКУВАННЯ РАКУ ЛЕГЕНІ, РАКУ ПІДШЛУНКОВОЇ ЗАЛОЗИ АБО КОЛОРЕКТАЛЬНОГО РАКУ | |
| EP2802586B1 (en) | Substituted imidazopyrazines as akt kinase inhibitors | |
| US9512169B2 (en) | 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments | |
| AU2017269871B2 (en) | (8-(phenylsulfonyl)-3,8-diazabicyclo(3.2.1)oct-3-yl) (1H-1,2,3-triazol-4-yl)methanones | |
| DK2864291T3 (en) | N- [4- (QUINOLIN-4-YLOXY) -CYCLOHEXYL (METHYL)] (HETERO) -ARYLCARBOXAMIDES AS ANDROGEN RECEPTOR ANTAGONISTS, THEIR PREPARATION AND USE AS MEDICINES | |
| TW202043203A (zh) | 1,2,4-三-3(2h)-酮化合物 | |
| CN104684896B (zh) | 作为雄激素受体拮抗剂的n‑[4‑(喹啉‑4‑基氧基)环己基(甲基)](杂)芳基甲酰胺、其制法及其用作药品的用途 | |
| CA3025420C (en) | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones | |
| HK1206346B (en) | N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| EP3555075A1 (en) | [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones | |
| WO2020157236A1 (en) | Pyridyl substituted dihydrooxadiazinones | |
| CA3047196A1 (en) | [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones | |
| CA3047191A1 (en) | [4-(phenylsulfonyl)piperazin-1-yl](1h-1,2,3-triazol-4-yl)methanones |